Clinical efficacy of JAK inhibitors such as tofacitinib in ulcerative colitis, along with emerging use in refractory SAPHO cases where TNF-α inhibitors fail or worsen symptoms, further supports the concept of shared cytokine-driven immunopathogenesis [3,29,30]. The gene discussed is TNF; the disease is ulcerative colitis.